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examine the effectiveness of sequential vs. initial combination therapy. Selected
patients had HbA1C7 at initiation of combination therapy (baseline) and no prior
insulin or DPP4i use. Initial combination was defined as initiation of PIO and DPP4i
within 30 days of each other; sequential combination was defined as having PIO
monotherapy for 2 months and initiation of a DPP4i within 1 year of the initiation
of PIO. Baseline characteristics were compared between cohorts using Wilcoxon
rank-sum and chi-square tests. HbA1C reduction at months 4, 8, 12, and 16 from
baseline was compared using linear models adjusting for demographic variables,
baseline HbA1C, diabetes duration, comorbidities, and medications. RESULTS: Pa-
tients starting initial (n250) and sequential (n211) combination with PIO and
DPP4i during 3/1/2010 – 2/28/2011 were identified. Patients in the two cohorts were
similar in demographics, disease duration, and most comorbidities; however, pa-
tients receiving initial combination therapy had higher average baseline HbA1C
(8.6 vs. 8.0; P0.001), a higher proportion with coronary artery disease (11.6% vs.
6.2%; P0.043), and lower proportions with hyperlipidemia (56.4% vs. 67.8%; P
0.012) and hypertension (62.4% vs. 72.0%; P 0.029). In adjusted analyses, initial
combination therapy was associated with greater reduction in HbA1C at months 12
(0.98 vs. 0.82, P0.034) and 16 (1.45 vs. 1.24, P0.048) than sequential combination
therapy. CONCLUSIONS: Initial combination therapy with PIO and DPP4i demon-
strated a significantly greater reduction in HbA1C than sequential combination
among patients with poorly controlled blood glucose.
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OBJECTIVES: Injectable pen therapy with insulin glargine (GLA-P) or the glucagon-
like peptide 1 (GLP-1) analog liraglutide (LIRA) may be initiated by type 2 diabetes
mellitus (T2DM) patients failing oral antidiabetic therapy. Real-world treatment
patterns among T2DM patients initiating these drugs were assessed using elec-
tronic medical record (EMR) data in this retrospective study. METHODS: The study
included adult T2DM patients who initiated GLA-P or LIRA at seven US endocrinol-
ogy practices. EMR data for4 months before treatment initiation (baseline), base-
line A1C and weight data, and 1 additional A1C measurement were available;
patients had 2 visits during a minimum of six months follow-up. Baseline char-
acteristics and clinical outcomes were assessed descriptively at the end of 1-year
follow-up. Patients were stratified by whether they were injectable-naive (IN) or
injectable-experienced (IE) at initiation. RESULTS: The study included 440 patients.
At baseline, GLA-P patients (n117), compared with LIRA patients (n323), were
older, had higher baseline A1C, and lower weight; more were male, fewer IE (60.7%
vs 65.3%). Insulin/GLP-1 were the only injectable in 49.3%/31.3% of LIRA IE vs 62.0%/
26.8% of GLA-P IE patients at baseline. Through follow-up, 88% of GLA-P and 91.6%
of LIRA patients remained on study treatment. A1C was significantly reduced in all
four treatment groups (range: 0.42% for LIRA IE to 1.38% for GLA-P IN). Weight
loss/maintenance occurred in 74.2% of LIRA vs 41.3% of GLA-P patients. Mean
change in weight/BMI was –2.5kg/–0.86kg/m2 for LIRA vs 2.4kg/0.85 kg/m2 for
GLA-P patients. No severe hypoglycemic events were reported. CONCLUSIONS:
Our data identify a trend in the real-world prescribing of LIRA and GLA-P to T2DM
patients with considerably different clinical profiles. This introduces challenges
when conducting real-world comparative effectiveness studies. Due to the small
sample size and descriptive nature of this study, these data should be confirmed by
future large scale studies.
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OBJECTIVES: T2DM patients failing on oral antidiabetic drugs (OADs) may initiate
injectable therapy with insulin glargine (GLA-P) or the glucagon-like peptide-1 an-
alog liraglutide (LIRA), but real-world data on treatment patterns and outcomes are
limited. This analysis reports results from a comparative effectiveness analysis on
data from the pilot retrospective phase of the Initiation of New Injectable Treat-
ment Introduced after Anti-diabetic Therapy with Oral-only Regimens (INITIATOR)
study. METHODS: Two independent administrative claims databases (OptumIn-
sight™ [OI] and HealthCore® [HC]) were used to identify adult US T2DM patients
with A1C 7.0% previously on OADs only, who initiated GLA-P or LIRA in 2010 and
had continuous health care coverage for6 months before (baseline) and 9 months
after (follow-up) initiation. Stringent 1:1 propensity score matching was used to
balance observed baseline differences between the cohorts. RESULTS: Data were
included for 350 matched patients from OI (175 per cohort) and 290 from HC (145 per
cohort). Baseline characteristics were similar for the matched cohorts. During fol-
low-up, treatment persistence was higher for GLA-P vs LIRA (OI: 63.4% vs 56.0%, P
0.213; HC: 68.3% vs 47.6%, P0.001). There were no significant differences in A1C
reduction from baseline among patients with available data. Hypoglycemia-related
events occurred at similarly low rates in both cohorts. Mean diabetes-related drug
costs were significantly lower among GLA-P vs LIRA patients (OI: $2,327 vs $3,121,
P0.001; HC: $2,149 vs $3,016, P0.001). CONCLUSIONS: Pilot phase data from the
INITIATOR study suggest that, for T2DM patients failing OADs, GLA-P may be as-
sociated with higher persistence, similar A1C reduction and low hypoglycemia
rates, and lower diabetes drug costs compared to LIRA. These results should be
considered exploratory, owing to small sample sizes and lack of weight data, and
await confirmation by data from the full-phase INITIATOR study.
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OBJECTIVES: To assess clinical and resource utilization outcomes between elderly
type 2 diabetes patients initiating basal insulin analog administered via pens vs.
vials. METHODS: An online survey of 352 U.S. primary care physicians was used to
collect retrospective patient chart data on 500 elderly type 2 diabetes patients who
initiated on basal insulin analog in 2009. Information on glycemic control, severe
hypoglycemic events, and diabetes-related health care resource utilization was
collected prior to initiation and over a 12-month study period following insulin
initiation. Information on adherence, both objective (measured via proportion of
days covered [PDC]) and physician-revised (based on a revision of the objective
PDC) was also collected for the study period. Multivariate regression analyses were
used to control for confounding factors. RESULTS:Over the study period, initiation
on pens, compared to vials, was associated with HbA1c levels 0.14 points lower
(P0.027). No differences were seen in the likelihood of reaching an HbA1c thresh-
olds of 7% (hazard ratio [HR]1.05, P0.738), though the likelihood was 27% and
55% higher for pen initiators for HbA1c thresholds of 7.5% (HR1.27, P0.041) and
8% (HR1.55, P0.001), respectively. Rates of severe hypoglycemic events, inpa-
tient, outpatient, and endocrinologist visits were similar between cohorts, but
rates of emergency room visits were 68% lower for the pen cohort (IRR0.32,
P0.017). No significant differences in objective adherence rates (PDC) were ob-
served (P0.080), while physician-revised adherence levels indicated a 2.2 percent-
age point higher adherence level for the pen cohort (P0.034). CONCLUSIONS:
Results from this study suggest that initiation on insulin pens, as compared to
vials, may be associated with better glycemic control, fewer emergency room visits,
and higher adherence levels (based on physician assessments) without an impact
to the incidence of severe hypoglycemic events. Objective adherence and other
resource utilization categories were not significantly different between the two
cohorts.
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OBJECTIVES: We previously identified a correlation between weight loss and gly-
cemic control in patients with type 2 diabetes (T2DM) newly treated with oral or
GLP-1 inhibitor therapy in the real-world setting. This study expands on those
findings by including previously treated patients and patients initiating insulin.
METHODS: This cohort study included T2DM patients age 18 years in an elec-
tronic medical record database from 2008-2011 prescribed a class of anti-diabetic
not previously used (index date), and with a baseline HbA1c 7.0%. Weight and
HbA1c changes from baseline were assessed at 6-months. Patients who lost3% of
body weight and attained HbA1c goal (7.0%) were identified. Logistic regression
was used to describe the association between weight loss and glycemic control
controlling for confounding factors, including initiation of insulin vs. other
therapies. RESULTS: The study included 861 patients. Mean (SD) age was 58.7 (12.3)
years; 54.8% were male. Most patients (85.9%) were prescribed a non-insulin agent.
Baseline HbA1c was 8.7% (1.6); weight was 103.6 kg (23.6). At 6 months, mean
weight change was -1.6 (5.3) kg (p0.13) and 31.8% lost weight. Mean change in
HbA1c was -1.2% (1.8) (p0.001). Overall, 42.9% attained HbA1c goal while 64.2% of
patients who lost weight and 32.9% of those who did not lose weight (p0.001)
attained goal. The OR for attaining HbA1c goal with weight loss 3% vs. no weight
loss was 3.60 (95% CI 2.66, 4.87) and was not significantly affected by insulin use.
CONCLUSIONS: Patients with uncontrolled T2DM prescribed a new class of anti-
diabetic and who lost weight were more likely to attain HbA1c goal at 6-months
than those who did not lose weight. These data are consistent with T2DM treat-
ment guidelines that emphasize the importance of weight loss and prioritization of
anti-diabetes agents that are not associated with weight gain.
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OBJECTIVES: To determine: 1) the response or cure rate of hyperthyroidism to fixed
doses of 370MBq (10mCi) and 555MBq (15mCi) Radioactive Iodine (RAI) therapy, and
2) the incidence of hypothyroidism at 6months post RAI therapy. METHODS: A
retrospective review of the records of 20 hyperthyroid patients treated with radio-
iodine to determine response rate of hyperthyroidism to two fixed dose regimens
of RAI therapy was carried out. Twelve (12) and 8 patients received 370MBq (10mCi)
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